MNPR-101-DFO*-89Zr
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor, Adult
Conditions
Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer
Trial Timeline
May 30, 2024 → Apr 1, 2026
NCT ID
NCT06337084About MNPR-101-DFO*-89Zr
MNPR-101-DFO*-89Zr is a phase 1 stage product being developed by Monopar Therapeutics for Solid Tumor, Adult. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06337084. Target conditions include Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06337084 | Phase 1 | Recruiting |
Competing Products
20 competing products in Solid Tumor, Adult